- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Tekla Healthcare Investors(HQH)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for HQH
11/13/2026: HQH (3-star) is currently NOT-A-BUY. Pass it for now.
Tekla Healthcare Investors is a closed-end investment fund that provides exposure to a professionally managed portfolio of healthcare, biotechnology, and medical device companies. The fund's primary strengths lie in its specialized domain expertise, diversified life sciences holdings, and consistent managed distribution policies that appeal to income-oriented investors. Its core growth story centers on capturing technological breakthroughs and potential M&A catalysts within emerging medical fields. However, the fund faces risks related to clinical trial volatility, healthcare regulatory pressures, and fluctuations in market valuation relative to net asset value. It is best suited for growth and dividend investors comfortable with single-sector equity volatility, who should monitor ongoing portfolio clinical milestones and broader biotechnology market trends.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The fund targets capital appreciation through high-growth biotechnology and healthcare equities. |
| Momentum investor | Strong fit while signal remains positive | Biotechnology holdings can experience sharp upward momentum during favorable clinical trial and M&A cycles. |
| Value investor | Mixed fit | Shares occasionally trade at discounts to net asset value, though underlying holdings are growth-oriented. |
| Dividend investor | Strong fit | The fund utilizes a managed distribution policy delivering high recurring payout yields. |
| Low-risk investor | Weak fit | Single-sector concentration in healthcare and biotechnology introduces elevated volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotechnology and emerging medical stocks experience sharp price swings. |
| Valuation risk | Medium | Fund shares can trade at varying premiums or discounts relative to underlying net asset value. |
| Competition risk (sector and fund competition) | Medium | The fund competes with numerous healthcare vehicles and alternative investment options for capital. |
| Business quality | Medium / high | Portfolio selection leverages professional analysis of top-tier medical and biotech innovators. |
| Dividend income | Medium | Distributions depend on realized capital gains and portfolio performance rather than fixed operating earnings. |
| Execution risk | Medium | Success relies heavily on the portfolio management team's ability to select winning healthcare equities. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.23B USD | Price to earnings Ratio 4.79 | 1Y Target Price - |
Price to earnings Ratio 4.79 | 1Y Target Price - | ||
Volume (30-day avg) 179.6K shares | Beta 0.74 | 52 Weeks Range 16.17 - 24.18 | Updated Date 11/15/2026 |
52 Weeks Range 16.17 - 24.18 | Updated Date 11/15/2026 | ||
Dividends yield (FY) 10.55% | Basic EPS (TTM) 4.47 |
Sector & Industry Intelligence
Sector
Financial Services
Constructive- Sentiment
- Bullish
- Momentum
- BUY Breadth Improving
- BUY participation
- 50.4%
- Active BUY / eligible
- 61 / 121
- 30-Day BUY Count Change
- +45
- Market state
- Bullish
More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.
Industry
Asset Management
- BUY participation
- 52.9%
- Active BUY / eligible
- 9 / 17
- 30-Day BUY Count Change
- +3
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Rolling Over
The price momentum is slowing down and beginning to turn downward.

Smooth
The stock has moved along a generally orderly path with only modest fluctuations.
Analysis of Past Performance
Type Stock | Historic Profit 74.62% | Avg. Invested days 102 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Investment Portfolio Returns | Capital appreciation, dividends, and realized gains from holdings in biotechnology, pharmaceuticals, and medical device companies. | You make money when the fund's underlying healthcare stocks increase in value and distribute payouts. |
Valuation
Trailing PE 4.79 | Forward PE - | Enterprise Value 1.06B | Price to Sales(TTM) 5.46 |
Enterprise Value 1.06B | Price to Sales(TTM) 5.46 | ||
Enterprise Value to Revenue 4.83 | Enterprise Value to EBITDA - | Shares Outstanding 57.19M | Shares Floating - |
Shares Outstanding 57.19M | Shares Floating - | ||
Percent Insiders - | Percent Institutions 24.12 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

